Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington's disease.

Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Hörsten S, Lescaudron L, Dunbar GL.

Behav Neurosci. 2012 Jun;126(3):479-87. doi: 10.1037/a0028028.

PMID:
22642889
2.

Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease.

Kirch RD, Meyer PT, Geisler S, Braun F, Gehrig S, Langen KJ, von Hörsten S, Nikkhah G, Cassel JC, Döbrössy MD.

Behav Brain Res. 2013 Feb 15;239:15-26. doi: 10.1016/j.bbr.2012.10.048. Epub 2012 Nov 5.

PMID:
23137697
3.

Subtle but progressive cognitive deficits in the female tgHD hemizygote rat as demonstrated by operant SILT performance.

Brooks S, Fielding S, Döbrössy M, von Hörsten S, Dunnett S.

Brain Res Bull. 2009 Jun 30;79(5):310-5. doi: 10.1016/j.brainresbull.2009.03.003. Epub 2009 Mar 28.

PMID:
19480990
4.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

5.

Altered emotional and motivational processing in the transgenic rat model for Huntington's disease.

Faure A, Höhn S, Von Hörsten S, Delatour B, Raber K, Le Blanc P, Desvignes N, Doyère V, El Massioui N.

Neurobiol Learn Mem. 2011 Jan;95(1):92-101. doi: 10.1016/j.nlm.2010.11.010. Epub 2010 Nov 25.

PMID:
21111837
6.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

7.

Memory deficits in the transgenic rat model of Huntington's disease.

Zeef DH, van Goethem NP, Vlamings R, Schaper F, Jahanshahi A, Hescham S, von Hörsten S, Prickaerts J, Temel Y.

Behav Brain Res. 2012 Feb 1;227(1):194-8. doi: 10.1016/j.bbr.2011.11.009. Epub 2011 Nov 15.

PMID:
22101303
8.

Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.

Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR.

J Neurosci. 2005 Apr 20;25(16):4169-80.

9.

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF.

J Comp Neurol. 2003 Oct 6;465(1):11-26.

PMID:
12926013
10.

Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease.

Zappacosta B, Monza D, Meoni C, Austoni L, Soliveri P, Gellera C, Alberti R, Mantero M, Penati G, Caraceni T, Girotti F.

Arch Neurol. 1996 Jun;53(6):493-7.

PMID:
8660149
11.

Severity of cognitive impairment in juvenile and late-onset Huntington disease.

Gómez-Tortosa E, del Barrio A, García Ruiz PJ, Pernaute RS, Benítez J, Barroso A, Jiménez FJ, García Yébenes J.

Arch Neurol. 1998 Jun;55(6):835-43.

PMID:
9626775
12.

Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.

Bode FJ, Stephan M, Wiehager S, Nguyen HP, Björkqvist M, von Hörsten S, Bauer A, Petersén A.

Behav Brain Res. 2009 Dec 14;205(1):175-82. doi: 10.1016/j.bbr.2009.06.031. Epub 2009 Jun 30.

PMID:
19573560
13.

Transgenic rat model of Huntington's disease.

von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O.

Hum Mol Genet. 2003 Mar 15;12(6):617-24.

14.

Weight loss in Huntington disease increases with higher CAG repeat number.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA.

Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e.

PMID:
18981372
15.

Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease.

Abada YS, Nguyen HP, Schreiber R, Ellenbroek B.

PLoS One. 2013 Jul 11;8(7):e68584. doi: 10.1371/journal.pone.0068584. Print 2013.

16.

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP.

Cell. 1996 Nov 1;87(3):493-506.

17.

Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington's disease.

Batcha AH, Greferath U, Jobling AI, Vessey KA, Ward MM, Nithianantharajah J, Hannan AJ, Kalloniatis M, Fletcher EL.

Neurobiol Dis. 2012 Mar;45(3):887-96. doi: 10.1016/j.nbd.2011.12.004. Epub 2011 Dec 11.

PMID:
22198376
18.

Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington's disease.

Abada YS, Schreiber R, Ellenbroek B.

Behav Brain Res. 2013 Feb 1;238:243-51. doi: 10.1016/j.bbr.2012.10.039. Epub 2012 Oct 30.

PMID:
23123142
19.

The use of transgenic and knock-in mice to study Huntington's disease.

Hickey MA, Chesselet MF.

Cytogenet Genome Res. 2003;100(1-4):276-86. Review.

PMID:
14526189
20.

[Huntington's disease: clinical and molecular genetics].

Warita H, Shiro Y, Kashihara K, Abe K.

Nihon Rinsho. 1999 Apr;57(4):896-9. Review. Japanese.

PMID:
10222786
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk